z-logo
open-access-imgOpen Access
Efficacy and safety of endoscopic retrograde cholangiopancreatography for the treatment of acute biliary pancreatitis with or without cholangitis
Author(s) -
Nguyễn Thị Kim Liên,
Nguyen Lam Tung,
Pham Thuy Dung,
Le Thi Anh Tuyet,
Vũ Văn Khiên
Publication year - 2021
Publication title -
y dược lâm sàng 108
Language(s) - English
Resource type - Journals
eISSN - 1859-2880
pISSN - 1859-2872
DOI - 10.52389/ydls.v16ita.1084
Subject(s) - endoscopic retrograde cholangiopancreatography , medicine , hepatology , concomitant , pancreatitis , acute pancreatitis , gastroenterology , retrospective cohort study
Objective: To evaluate the result of endoscopic retrograde cholangiopancreatography (ERCP) for treatment of acute biliary pancreatitis (ABP) with or without cholangitis. Subject and method: A retrospective cohort study, 30 patients of ABP at Institute of Gastroenterology and Hepatology, 108 Military Central Hospital, from January 2019 to November 2021. Result: We divided the patients into 2 groups: 19 patients ABP with cholangitis, 11 patients without cholangitis. Mean age: 60.7 ± 17.9 (26 - 92), male/female (1.5). The technical success rates were 94.7% and 100%, the clinical success rates were 100% and 90.9% of the two groups with and without cholangitis, respectively. The concomitant cholangitis was not associated with the timing of ERCP (p=0.192), technical success rate (p=0.439), and clinical success rate (p=0.367). And the total length of hospital stay was not different between the two groups (7.7 ± 3 vs. 7.7 ± 4.1 days, p=0.974). No significant differences were found in the duration of hospital after ERCP or procedural-related complications, in patients with acute biliary pancreatitis, according to the concomitant disease (with vs without cholangitis). Conclusion: These findings support ERCP could be performed effectively and safely in acute biliary pancreatitis with or without cholangitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here